Surgery Partners, Inc. (SGRY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SGRY Revenue Growth
Revenue Breakdown (FY 2025)
SGRY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SGRY Revenue Analysis (2014–2025)
As of May 8, 2026, Surgery Partners, Inc. (SGRY) generated trailing twelve-month (TTM) revenue of $3.34 billion, reflecting modest growth of +4.5% year-over-year. The most recent quarter (Q1 2026) recorded $810.9 million in revenue, down 8.4% sequentially.
Looking at the longer-term picture, SGRY's 5-year compound annual growth rate (CAGR) stands at +12.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $3.31 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows SGRY's business is primarily driven by Healthcare Organization, Patient Service (49%), Private Insurance (26%), and Government Revenue (21%).
When compared to Healthcare sector peers including USPH (+4.0% YoY), SEM (+29.2% YoY), and AMSF (+7.8% YoY), SGRY has underperformed the peer group in terms of revenue growth. Compare SGRY vs USPH →
SGRY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SGRYCurrent | $3.3B | +4.5% | +12.2% | 11.8% | |
 USPH | $781M | +4.0% | +13.0% | 10.3% | |
 SEM | $5.5B | +29.2% | -0.3% | 6.1% | |
 AMSF | $317M | +7.8% | -1.3% | 18.6% | |
 NHC | $1.5B | +22.1% | +8.4% | 8.7% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% |
SGRY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.31B | +6.2% | $765.0M | 23.1% | $389.5M | 11.8% |
| 2024 | $3.11B | +13.5% | $745.6M | 23.9% | $348.8M | 11.2% |
| 2023 | $2.74B | +8.0% | $647.5M | 23.6% | $328.0M | 12.0% |
| 2022 | $2.54B | +14.1% | $574.9M | 22.6% | $345.2M | 13.6% |
| 2021 | $2.23B | +19.6% | $491.4M | 22.1% | $302.2M | 13.6% |
| 2020 | $1.86B | +1.6% | $379.8M | 20.4% | $183.0M | 9.8% |
| 2019 | $1.83B | +3.4% | $423.8M | 23.1% | $235.9M | 12.9% |
| 2018 | $1.77B | +32.1% | $410.0M | 23.1% | $77.8M | 4.4% |
| 2017 | $1.34B | +17.1% | $327.4M | 24.4% | $158.2M | 11.8% |
| 2016 | $1.15B | +19.3% | $324.2M | 28.3% | $196.5M | 17.2% |
See SGRY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGRY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SGRY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSGRY — Frequently Asked Questions
Quick answers to the most common questions about buying SGRY stock.
Is SGRY's revenue growth accelerating or slowing?
SGRY revenue growth slowed to +4.5%, below the 5-year CAGR of +12.2%. TTM revenue is $3.3B. The deceleration marks a shift from historical growth rates.
What is SGRY's long-term revenue growth rate?
Surgery Partners, Inc.'s 5-year revenue CAGR of +12.2% reflects the variable expansion pattern. Current YoY growth of +4.5% is near this long-term average.
How is SGRY's revenue distributed by segment?
SGRY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.